<?xml version='1.0' encoding='utf-8'?>
<document id="18201587"><sentence text="Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease."><entity charOffset="40-50" id="DDI-PubMed.18201587.s1.e0" text="duloxetine" /><entity charOffset="55-68" id="DDI-PubMed.18201587.s1.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.18201587.s1.e0" e2="DDI-PubMed.18201587.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18201587.s1.e0" e2="DDI-PubMed.18201587.s1.e1" /></sentence><sentence text="Recent evidence suggests that duloxetine may increase the effect of warfarin, thereby increasing the possibility of bleeding"><entity charOffset="30-40" id="DDI-PubMed.18201587.s2.e0" text="duloxetine" /></sentence><sentence text=" However, a MEDLINE search for articles published between 1980 and May 2007 (terms: duloxetine, anticoagulants, acenocoumarol, and interaction; no language restriction) did not yield any reports of an interaction between concomitant use of duloxetine and acenocoumarol"><entity charOffset="84-94" id="DDI-PubMed.18201587.s3.e0" text="duloxetine" /><entity charOffset="112-125" id="DDI-PubMed.18201587.s3.e1" text="acenocoumarol" /><entity charOffset="240-250" id="DDI-PubMed.18201587.s3.e2" text="duloxetine" /><entity charOffset="255-268" id="DDI-PubMed.18201587.s3.e3" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e0" e2="DDI-PubMed.18201587.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e0" e2="DDI-PubMed.18201587.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e0" e2="DDI-PubMed.18201587.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e0" e2="DDI-PubMed.18201587.s3.e3" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e1" e2="DDI-PubMed.18201587.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e1" e2="DDI-PubMed.18201587.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e1" e2="DDI-PubMed.18201587.s3.e3" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e2" e2="DDI-PubMed.18201587.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18201587.s3.e2" e2="DDI-PubMed.18201587.s3.e3" /></sentence><sentence text="" /><sentence text="The aim of this study was to describe a potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease"><entity charOffset="80-90" id="DDI-PubMed.18201587.s5.e0" text="duloxetine" /><entity charOffset="95-108" id="DDI-PubMed.18201587.s5.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.18201587.s5.e0" e2="DDI-PubMed.18201587.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18201587.s5.e0" e2="DDI-PubMed.18201587.s5.e1" /></sentence><sentence text=" The possible mechanism of this potential interaction is examined" /><sentence text="" /><sentence text="This report presents the case of a 63-year-old white female patient weighing 64 kg receiving oral treatment with the synthetic coumarin anticoagulant acenocoumarol (mean dosage, 9 mg/wk) for 8 years who experienced a persistent (3-week) decrease in international normalized ratio (INR) to 1"><entity charOffset="127-135" id="DDI-PubMed.18201587.s8.e0" text="coumarin" /><entity charOffset="150-163" id="DDI-PubMed.18201587.s8.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.18201587.s8.e0" e2="DDI-PubMed.18201587.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18201587.s8.e0" e2="DDI-PubMed.18201587.s8.e1" /></sentence><sentence text="49 after taking a single 60-mg dose of duloxetine"><entity charOffset="39-49" id="DDI-PubMed.18201587.s9.e0" text="duloxetine" /></sentence><sentence text=" Three weeks after discontinuation of duloxetine, the INR returned to the previous baseline level (2"><entity charOffset="38-48" id="DDI-PubMed.18201587.s10.e0" text="duloxetine" /></sentence><sentence text="58)" /><sentence text="" /><sentence text="This case report suggests a possible drug-drug interaction between duloxetine and acenocoumarol"><entity charOffset="67-77" id="DDI-PubMed.18201587.s13.e0" text="duloxetine" /><entity charOffset="82-95" id="DDI-PubMed.18201587.s13.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.18201587.s13.e0" e2="DDI-PubMed.18201587.s13.e0" /><pair ddi="false" e1="DDI-PubMed.18201587.s13.e0" e2="DDI-PubMed.18201587.s13.e1" /></sentence><sentence text=" Duloxetine should be administered with caution in patients receiving acenocoumarol therapy"><entity charOffset="1-11" id="DDI-PubMed.18201587.s14.e0" text="Duloxetine" /><entity charOffset="70-83" id="DDI-PubMed.18201587.s14.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.18201587.s14.e0" e2="DDI-PubMed.18201587.s14.e0" /><pair ddi="false" e1="DDI-PubMed.18201587.s14.e0" e2="DDI-PubMed.18201587.s14.e1" /></sentence><sentence text="" /></document>